NASDAQ · Biotechnology

GH Research PLC (GHRS) Stock

$18.07 -2.32% NASDAQ: GHRS Healthcare

Valuation

MetricValue
Price$18.07
Market Cap$1.24B
P/E Ratio-22.71
P/B Ratio4.20
P/S Ratio0.00
EPS (TTM)$-0.79
52-Week High$31.44
52-Week Low$12.04
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-20.86%
ROA-16.72%
ROCE-19.87%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio35.75

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-15.0M$-31.0M$-41.0M$-50.0M$-61.0M
Net Profit$-9.0M$-22.0M$-36.0M$-39.0M$-48.0M
EPS$-0.18$-0.14$-0.68$-0.75$-0.79
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$280.0M$254.0M$226.0M$188.0M$288.0M
Total Liabilities$3.0M$5.0M$7.0M$9.0M$9.0M
Cash$277.0M$166.0M$78.0M$101.0M$246.0M
Borrowings$0$0$1.0M$1.0M$1.0M

Latest News

The Race to Commercialize the World’s Most Powerful Psychedelic WSJ · Jul 14, 2026 Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says Proactive · Jul 13, 2026 Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026? Zacks · Jul 2, 2026 AtaiBeckley Reflects a New Push for Rapid-Acting Mental Health Drugs Zacks · Jul 2, 2026 AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026 Zacks · Jul 2, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-15.0M$-26.0M$-33.0M$-42.0M$-44.0M
Investing Cash Flow$0$-85.0M$-54.0M$65.0M$46.0M
Financing Cash Flow$-23.0M$0$0$0$0
Net Cash Flow$271.0M$-111.0M$-88.0M$22.0M$145.0M
Free Cash Flow$-15.0M$-26.0M$-33.0M$-42.0M$-44.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.79
EV / EBITDA-19.64
FCF Yield-3.37%
Quick Ratio28.70
Interest Coverage-355.41
Return 1Y71.24%
Return 3Y118.17%
Return 5Y65.11%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANROAlto Neuroscience, Inc. $21.97 -1.04% -9.71 $862.15M 0.00%
BHVNBiohaven Ltd. $13.88 -5.51% -2.77 $2.10B 0.00%
DFTXDefinium Therapeutics, Inc. $35.67 -0.92% -10.87 $4.79B 0.00%
LBRXLB Pharmaceuticals Inc $38.73 -1.75% -12.45 $1.25B 0.00%
MPLTMapLight Therapeutics, Inc. $7.97 -3.39% -1.90 $339.67M 0.00%

About GH Research PLC

GH Research PLC is led by CEO Velichka Valcheva, employs 50 people, headquartered in IE, publicly traded since 2021.

GH Research PLC (GHRS) stock trades at $18.07 with a market capitalization of $1.24B. The stock is valued at a negative price-to-earnings (P/E) ratio of -22.71, reflecting a net loss over the last twelve months, price-to-book of 4.20, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $12.04 and $31.44, and currently trades 42.5% below its 52-week high.

On profitability, GH Research PLC generates a return on equity (ROE) of -20.86% (negative, reflecting a net loss), return on capital employed of -19.87%.

GH Research PLC by the numbers, 2019–2025

Between 2019 and 2025 GH Research PLC reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit was $-48.0M in 2025.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-62.0M.

Borrowings stand at $1.0M, cash from operations was $-44.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged -13.5% over five years, and was -17.1% in the most recent year.

The share price itself has compounded at —% a year over five years, 21.5% over three, 62.0% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

GH Research PLC (GHRS) — frequently asked questions

What is GH Research PLC (GHRS) stock price today?

GH Research PLC (GHRS) is currently trading at $18.07, down 2.32% today.

What is GHRS P/E ratio?

GH Research PLC's P/E ratio is -22.71. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is GHRS return on equity (ROE)?

GH Research PLC's return on equity (ROE) is -20.86%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is GH Research PLC's market cap?

GH Research PLC has a market capitalization of $1.24B.

Does GHRS pay a dividend?

GH Research PLC is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does GHRS carry?

GH Research PLC has a debt-to-equity ratio of 0.00. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is GHRS's profit margin?

GH Research PLC reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.

What sector is GHRS in?

GH Research PLC is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is GHRS listed on?

GH Research PLC trades on NASDAQ under the ticker GHRS.

What is GHRS's 52-week range?

Over the last year GH Research PLC has traded between $12.04 and $31.44.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens GHRS currently matches

On the figures above, GH Research PLC passes the filters for 8 of our ready-made screens, among them Low Debt Stocks, Small Cap Stocks, Debt Free Stocks Under $100. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Low Debt StocksSmall Cap StocksDebt Free Stocks Under $100Debt Free StocksStocks Under $100Stocks Under $50Debt to Equity Below 1 StocksHigh Current Ratio Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.